327
Participants
Start Date
June 27, 2023
Primary Completion Date
May 30, 2029
Study Completion Date
May 30, 2029
HRO761
Tablet
pembrolizumab
Concentrate for solution for infusion
irinotecan
Concentrate for solution for infusion
RECRUITING
Novartis Investigative Site, Brussels
RECRUITING
Novartis Investigative Site, Taipei
RECRUITING
Memorial Sloan Kettering, New York
RECRUITING
Columbia University Medical Ctr, New York
RECRUITING
Novartis Investigative Site, Marseille
RECRUITING
Novartis Investigative Site, Stockholm
RECRUITING
Novartis Investigative Site, Rozzano
RECRUITING
Novartis Investigative Site, Milan
RECRUITING
Novartis Investigative Site, Madrid
RECRUITING
Novartis Investigative Site, Madrid
RECRUITING
Novartis Investigative Site, Toulouse
RECRUITING
Novartis Investigative Site, Bordeaux
RECRUITING
Novartis Investigative Site, Essen
RECRUITING
Novartis Investigative Site, Valencia
RECRUITING
Univ of TX MD Anderson Cancer Cntr, Houston
RECRUITING
Novartis Investigative Site, Ulm
RECRUITING
University of California LA, Los Angeles
RECRUITING
UCSF, San Francisco
RECRUITING
Novartis Investigative Site, Beijing
RECRUITING
Novartis Investigative Site, Singapore
RECRUITING
Novartis Investigative Site, Guangzhou
RECRUITING
Novartis Investigative Site, Tel Aviv
RECRUITING
Dana Farber Cancer Institute, Boston
RECRUITING
Novartis Investigative Site, Jena
RECRUITING
Novartis Investigative Site, Kashiwa
RECRUITING
Novartis Investigative Site, Oslo
RECRUITING
Novartis Investigative Site, Seoul
RECRUITING
Novartis Investigative Site, Barcelona
RECRUITING
Novartis Investigative Site, London
RECRUITING
Novartis Investigative Site, Oxford
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY